GlassScriptPhysician profile
Ashley Matkins
NPI 1306535521
$2,945.86
in general payments reported to CMS, 2019-2025
27 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $40.66 · 2024: $1,721 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $688.10 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $405.19 | 2024-2025 | |
| Novo Nordisk INC | $300.72 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $245.46 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $216.29 | 2024-2025 | |
| Shield Therapeutics INC | $168.57 | 2024-2025 | |
| Exact Sciences Corporation | $123.26 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.22 | 2024 | Synjardy, Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $81.12 | 2024-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $67.57 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $56.17 | 2024 | Gemtesa |
| Seqirus USA INC | $50.55 | 2024-2025 | Flucelvax, Fluad |
| Astellas Pharma US INC | $50.07 | 2024-2025 | Veozah |
| Noven Therapeutics, LLC | $47.44 | 2024-2025 | Xelstrym |
| Corcept Therapeutics | $45.45 | 2024-2025 | Korlym |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $37.47 | 2024-2025 | |
| Glaxosmithkline, LLC. | $35.50 | 2024 | Arexvy, Shingrix |
| Medtronic, INC. | $33.14 | 2025 | Intellis Adaptivestim |
| Edwards Lifesciences Corporation | $31.30 | 2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $30.43 | 2024 | Krystexxa |
| Vanda Pharmaceuticals INC. | $29.66 | 2025 | Hetlioz, Fanapt |
| Otsuka America Pharmaceutical, INC. | $21.37 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $20.83 | 2025 | Capvaxive, Gardasil 9 |
| Boston Scientific Corporation | $19.81 | 2024 | Watchman Flx |
| Axsome Therapeutics, INC. | $17.91 | 2025 | Auvelity |
| Corium, LLC | $17.78 | 2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $16.48 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Matkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.